Literature DB >> 23231803

Colposcopic management of abnormal cervical cytology and histology.

James Bentley1.   

Abstract

OBJECTIVE: To provide a guideline for managing abnormal cytology results after screening for cervical cancer, to clarify the appropriate algorithms for follow-up after treatment, and to promote the best possible care for women while ensuring efficient use of available resources. OUTCOMES: Women with abnormal cytology are at risk of developing cervical cancer; appropriate triage and treatment will reduce this risk. This guideline will facilitate implementation of common standards across Canada, moving away from the current trend of individual guidelines in each province and territory. EVIDENCE: Published literature was retrieved through searches of PubMed or Medline, CINAHL, and The Cochrane Library in October 2008 using appropriate controlled vocabulary (e.g., colposcopy, cervical dysplasia) and key words (e.g., colposcopy management, CIN, AGC, cervical dysplasia, LEEP, LLETZ, HPV testing, cervical dysplasia triage). Results were restricted to systematic reviews, randomized control trials/controlled clinical trials, and observational studies. There were no date or language restrictions. Searches were updated on a regular basis and incorporated in the guideline to July 2012. Grey (unpublished) literature was identified through searching the websites of health technology assessment and health technology assessment-related agencies, clinical practice guideline collections, and national and international medical specialty societies. Expert opinion from published peer-reviewed literature and evidence from clinical trials is summarized. Consensus opinion is outlined when evidence is insufficient. VALUES: The quality of the evidence is rated using the criteria described by the Canadian Task Force on Preventive Health Care (Table 1). VALIDATION: This guideline has been reviewed for accuracy from content experts in cytology, pathology, and cervical screening programs. Guideline content was also compared with similar documents from other organizations including the American Society for Colposcopy and Cervical Pathology, the British Society for Colposcopy and Cervical Pathology, and the European Cancer Network.

Entities:  

Mesh:

Year:  2012        PMID: 23231803     DOI: 10.1016/S1701-2163(16)35468-8

Source DB:  PubMed          Journal:  J Obstet Gynaecol Can        ISSN: 1701-2163


  22 in total

1.  The organization of colposcopy services in Ontario: recommended framework.

Authors:  J Murphy; N P Varela; L Elit; A Lytwyn; M Yudin; M Shier; V Wu; S El-Khatib
Journal:  Curr Oncol       Date:  2015-08       Impact factor: 3.677

2.  ASCCP Colposcopy Standards: Colposcopy Quality Improvement Recommendations for the United States.

Authors:  Edward J Mayeaux; Akiva P Novetsky; David Chelmow; Francisco Garcia; Kim Choma; Angela H Liu; Theognosia Papasozomenos; Mark H Einstein; L Stewart Massad; Nicolas Wentzensen; Alan G Waxman; Christine Conageski; Michelle J Khan; Warner K Huh
Journal:  J Low Genit Tract Dis       Date:  2017-10       Impact factor: 1.925

3.  Trends in Colposcopy Volume: Where Do We Go From Here?

Authors:  Emily E Landers; Britt K Erickson; Sejong Bae; Warner K Huh
Journal:  J Low Genit Tract Dis       Date:  2016-10       Impact factor: 1.925

4.  Measuring colposcopy quality in Canada: development of population-based indicators.

Authors:  K Decker; N Baines; C Muzyka; M Lee; M H Mayrand; H Yang; S Fung; D Mercer; S McFaul; R Kupets; R Savoie; R Lotocki; J Bentley
Journal:  Curr Oncol       Date:  2019-06-01       Impact factor: 3.677

5.  Effect of human papillomavirus vaccination on cervical cancer screening in Alberta.

Authors:  Jong Kim; Christopher Bell; Maggie Sun; Gordon Kliewer; Linan Xu; Maria McInerney; Lawrence W Svenson; Huiming Yang
Journal:  CMAJ       Date:  2016-07-04       Impact factor: 8.262

6.  Course of cervical intraepithelial neoplasia diagnosed during pregnancy.

Authors:  Donata Grimm; Isabelle Lang; Katharina Prieske; Anna Jaeger; Volkmar Müller; Sascha Kuerti; Eike Burandt; Susanne Lezius; Barbara Schmalfeldt; Linn Woelber
Journal:  Arch Gynecol Obstet       Date:  2020-04-22       Impact factor: 2.344

7.  The impact of the COVID-19 pandemic on the Ontario Cervical Screening Program, colposcopy and treatment services in Ontario, Canada: a population-based study.

Authors:  O Meggetto; N Jembere; J Gao; M J Walker; M Rey; L Rabeneck; K J Murphy; R Kupets
Journal:  BJOG       Date:  2021-05-31       Impact factor: 7.331

8.  Distribution of cervical intraepithelial neoplasia on the cervix in Chinese women: pooled analysis of 19 population based screening studies.

Authors:  Yu-qian Zhao; Irene J Chang; Fang-hui Zhao; Shang-ying Hu; Jennifer S Smith; Xun Zhang; Shu-min Li; Ping Bai; Wen-hua Zhang; You-lin Qiao
Journal:  BMC Cancer       Date:  2015-06-27       Impact factor: 4.430

9.  hr-HPV testing in the follow-up of women with cytological abnormalities and negative colposcopy.

Authors:  F Carozzi; C B Visioli; M Confortini; A Iossa; P Mantellini; E Burroni; M Zappa
Journal:  Br J Cancer       Date:  2013-09-05       Impact factor: 7.640

10.  Cost-effectiveness analysis of anal cancer screening in women with cervical neoplasia in British Columbia, Canada.

Authors:  I Cromwell; M Gaudet; S J Peacock; C Aquino-Parsons
Journal:  BMC Health Serv Res       Date:  2016-06-27       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.